Rotterdam, Zuid-Holland, The Netherlands The venture was found in Europe in The Netherlands. The main department of described VC is located in the Rotterdam.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Erasmus MC Biomedical Fund, startups are often financed by Thuja Capital, KBC, Forbion Capital Partners. The meaningful sponsors for the fund in investment in the same round are Forbion Capital Partners, Thuja Capital, Omnes Capital. In the next rounds fund is usually obtained by Omnes Capital, Forbion Capital Partners, Thuja Capital.
The fund is constantly included in less than 2 deals per year. Comparing to the other companies, this Erasmus MC Biomedical Fund performs on 12 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2017. The real fund results show that this VC is 3 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2009.
Among the various public portfolio startups of the fund, we may underline arGEN-X For fund there is a match between the location of its establishment and the land of its numerous investments - The Netherlands. Among the most successful fund investment fields, there are Clinical Trials, Therapeutics. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
arGEN-X | $38M | 01 Dec 2011 | Rotterdam, South Holland, Netherlands | ||
arGEN-X | $4M | 11 Feb 2010 | Rotterdam, South Holland, Netherlands | ||
arGEN-X | $13M | 10 Sep 2009 | Rotterdam, South Holland | ||
Cavadis | 26 May 2009 | Utrecht, Utrecht, Netherlands |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
arGEN-X | $38M | 01 Dec 2011 | Rotterdam, South Holland, Netherlands | ||
arGEN-X | $4M | 11 Feb 2010 | Rotterdam, South Holland, Netherlands | ||
arGEN-X | $13M | 10 Sep 2009 | Rotterdam, South Holland | ||
Cavadis | 26 May 2009 | Utrecht, Utrecht, Netherlands |
